In these cells, abemaciclib decreased CDK6 phosphorylation and downregulated both p-Rb and Rb levels (Figure 1B), in accordance with data from literature showing that CDK4/6 inhibitors reduce Rb phosphorylation and concomitantly decrease the expression of total Rb protein in multiple cancer models (28). Here, CDK6 is linked to cancer.